スペインで最高の前立腺癌医師 - トップ6名の医師

Galceran教授はバル・デブロン病院でスペインの泌尿生殖器がんユニットを率い、900件以上の手術実績と全国臨床試験を有する前立腺がんの専門家です。

• 泌尿生殖器腫瘍学における39年の経験の診療経験
• 前立腺がん免疫療法および分子診断学のパイオニア
• がん治療に関する査読付き論文120本以上の著者
• スペイン泌尿生殖器腫瘍グループ（SOGUG）の共同創設者
• ASCO・ESMOの会員であり、欧州腫瘍学認定資格を保有

ラモン・ミラルベル教授は、特に前立腺がんにおける放射線腫瘍学の世界的に著名な専門家です。CERN（欧州原子核研究機構）と協力しています。

専門分野

ミラルベル教授は、フォーカスされたラジオサージャリー（ガンマナイフ、サイバーナイフ、SIRT、IMRT）、放射線療法による前立腺がんの治療を専門としています。

職歴

• 1999年から — セントロ・メディコ・テクノンの放射線腫瘍学部門長

学歴

• 1979-1984 — サンパウ大学病院（スペイン） — 医学一般の学位、放射線腫瘍学のトレーニング
• 1983 — ロイヤルマースデン病院の放射線治療部門（英国） — トレーニング
• 1985 — シティ・オブ・ホープ国立医療センターの放射線腫瘍学部門（米国） — インターンシップ
• 1987-1989 — ハーバード大学のサイクロトロン研究所（米国） — 研究員。
• 1997 — ジュネーブ大学医学部（スイス） — 医学と外科の博士号。

受賞

• スイス放射線生物学および医学物理学会の放射線腫瘍学のためのバリアン賞

科学研究

100以上の科学的な出版物を書いています。画像誘導放射線療法、高齢者における進行した前立腺がん治療、陽子療法の研究を提供しています。

組織への所属

• スイス放射線腫瘍学会。

Dr. Enrique Grande, MD, PhD, MSc, is a medical oncologist with more than 20 years of experience. He is an international expert in genitourinary and neuroendocrine tumors. He directs the Medical Oncology Department and the One Oncology Madrid Cancer Program at QuirónSalud, Spain’s largest private healthcare network. He leads an integrated, multidisciplinary model with access to targeted therapies and clinical trials.

He is a pioneer in precision oncology. He uses molecular profiling and biomarker-based care. He has authored more than 300 peer-reviewed papers. He serves as a principal investigator and sits on steering committees for many international trials. These studies help set standards of care in urothelial bladder and neuroendocrine tumors. He contributes to guidelines and programs at ESMO, ASCO, ENETS, and EAU.

アントニオ・アルカラス博士はテクノン医療センター（バルセロナ、スペイン）の泌尿器科および腎移植部門を率いています。

アントニオ・アルカラス博士は、30年以上の経験を持つスペインの有名な外科医、泌尿器腫瘍学者、移植専門医です。彼のマネジメントの下、泌尿生殖器系の病理を治療するために500を超える成功した手術が行われました。多くの外科的介入は、低侵襲技術（腹腔鏡による経膣的腎臓摘出術、腎摘出術、腎移植を含む）で行われました。アントニオ・アルカラスの主な専門分野は、前立腺癌の治療です。

腎臓、膀胱、副腎、精巣、尿管、および他の泌尿器系の臓器の腫瘍性疾患の治療は、ダ・ヴィンチ手術ロボットシステムを用いた伝統的な外科的方法および革新的な方法によって提供されます。

アントニオ・アルカラス博士はまた、たとえば停留精巣のような子供の先天性病態も治療します。

医師は下記のような権威ある専門コミュニティのメンバーです：

• アメリカ泌尿科連合；
• スペイン泌尿器科協会；
• 欧州泌尿器科学会。

Dr. Joseba Rebollo Liceaga is a seasoned medical oncologist with a comprehensive background in oncology.​

Education and Training:

Graduated in Medicine and Surgery from the University of Navarra (1985).​

Completed residency in Oncology in 1987.​

Specialist in Medical Oncology at the Clínica Universidad de Navarra (1991).​

Professional Experience:

Head of the Oncology Department at Clínica San Miguel de Navarra (1991–2004).​

Associate Physician at the University Clinic of the Faculty of Medicine, University of Navarra (1995–2002).​

Adjunct Physician at the Oncology Platform, Hospital Quirónsalud Torrevieja (2004–2014).

Head of the Oncology Department at Hospital General de Villalba (2014–2019).​

Currently practices as a Medical Oncology Specialist at Quirónsalud Alicante.​

Certifications and Training:

Completed multiple accredited courses in Multidisciplinary Oncology between 2003 and 2006.​

Research and Publications:

Authored research on electrochemotherapy and multidisciplinary treatment approaches in oncology.

Academic Education:

• Bachelor of Medicine and Surgery. University of Barcelona.
• Doctor in medicine. University of Barcelona. Extraordinary prize for doctoral thesis.
• Training in translational research thanks to a post-doctoral stay at Memorial Sloan-Kettering Cancer Center (New York, USA).

Professional Experience:

• Medical Oncologist specialized in urological cancer. Her areas of expertise are prostate cancer, kidney, bladder and urinary tract cancer, and testicular cancer.
• She currently works as a Senior Consultant in the Medical Oncology Service of the Hospital Clínic de Barcelona, ​​where she is responsible for urological cancer. 
• At HM Delfos, from Medical Oncology, she is responsible for the care of patients with urological cancer, from a multidisciplinary approach in coordination with the different specialists (urology, radiotherapy, pathology) through joint work and the Tumor Committee. She is also responsible for the introduction of new therapies and the development of clinical trial projects in this area.

Scientific and Teaching Activity:

• Associate Professor of the Faculty of Medicine of the Clinical Hospital. University of Barcelona. 
• Teaching in the subject of Medical Oncology, of the 5th year of the Degree in Medicine and Surgery at the University of Barcelona. She has been the director of several Final Degree projects for medical students in ​​urological cancer.
• Teacher and Director of the subject "Prostate Cancer" of the Master of Biomedicine. University of Barcelona.
• Teacher and Director of the subject "Comprehensive management of the uro-oncological patient", of the Master of Uro-Oncology of Advanced Medical Competences. University of Barcelona. 
• Direction of several doctoral theses on prostate cancer.
• Extensive experience in the training of Residents in Medical Oncology at the Clinical Hospital de Barcelona.
• Extensive teaching experience in scientific courses and symposiums.
• Internship tutor for students of the Master in Art Therapy at Escuela Metáfora. Art therapy in cancer patients at Hospital Clinic.
• Coordinator of Mindfulness training workshops in Oncology.
• Clinical research:   Extensive experience as principal investigator of multiple clinical trials, phase I, II and III, of new therapies in urological cancer.
• Translational research: Researcher at the August Pi i Sunyer Biomedical Research Institute (IDIBAPS). Leader of the Prostate Cancer working group, within the Translational Genomics Laboratory and Targeted Therapy in Solid Tumors. Her fundamental line of research is based on the investigation of resistance mechanisms to prostate cancer treatments and the study of biomarkers that allow progress towards personalized medicine in this disease.
• She has published more than 140 scientific articles in international journals.

Areas of Professional Interest:

• Her interest as a professional is to provide the best care for patients with urological cancer from all areas: the best care on an individual basis and offer them the best available treatment or the possibility of having access to new treatments within clinical trials. 
• In addition, she has a great interest in promoting comprehensive care for patients and their families.